ArticleScientific reports2016
Mesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Beyond animal models: using human pluripotent stem cell-derived stem and progenitor cells to predict cytotoxicity in normal tissues.Pathology oncology research : POR · 2026Article
- The Influence of Cisplatin on Functionality and Surface Characteristics of Mesenchymal Stromal Cells In Vitro.International journal of molecular sciences · 2025Article
- Platinum chemotherapeutic-induced oxidative stress affects the transcriptional response of DNA repair genes in murine mesenchymal stem cells.American journal of stem cells · 2025Article
- Effects of tumor treating fields (TTFields) on human mesenchymal stromal cells.Journal of neuro-oncology · 2024Article
- Functionality of bone marrow mesenchymal stromal cells derived from head and neck cancer patients - A FDA-IND enabling study regarding MSC-based treatments for radiation-induced xerostomia.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024Article
- Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients.Bioengineering (Basel, Switzerland) · 2023Review
- Article
- An overview of mesenchymal stem cells and their potential therapeutic benefits in cancer therapy.Oncology letters · 2021Review
- Mesenchymal stem cells in cancer therapy; the art of harnessing a foe to a friend.Iranian journal of basic medical sciences · 2021Review
- Review
- Recent Advances on Drug-Loaded Mesenchymal Stem Cells With Anti-neoplastic Agents for Targeted Treatment of Cancer.Frontiers in bioengineering and biotechnology · 2020Review
- Enhancement of the Therapeutic Capacity of Mesenchymal Stem Cells by Genetic Modification: A Systematic Review.Frontiers in cell and developmental biology · 2020Review
- Human mesenchymal stem cells are resistant to UV-B irradiation.Scientific reports · 2019Article
- The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage.Stem cell reviews and reports · 2019Review
- [Application of mesenchymal stem cells in antineoplastic drugs delivery for tumor-targeted therapy].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2018Review
- Chemotherapy-induced metastasis: mechanisms and translational opportunities.Clinical & experimental metastasis · 2018Review
- Mesenchymal stem cells show functional defect and decreased anti-cancer effect after exposure to chemotherapeutic drugs.Journal of biomedical science · 2018Article
- Human mesenchymal stem cells lose their functional properties after paclitaxel treatment.Scientific reports · 2018Article
- Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor Treatment.Frontiers in pharmacology · 2018Review
- Molecular markers of DNA damage and repair in cervical cancer patients treated with cisplatin neoadjuvant chemotherapy: an exploratory study.Cell stress & chaperones · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) aid the regeneration of tissues damaged by treatment with cisplatin. However, the effects of this cytotoxic drug on the stem cells have been largely unknown. Here we demonstrate that human bone marrow-derived MSCs are relatively resistant to cisplatin treatment and show resistance levels comparable to these of differentiated fibroblasts. Cisplatin did not affect cellular morphology, adhesion or induction of apoptosis in MSCs. The potential for differentiation was preserved after exposure to cisplatin, and established MSC surface markers were observed to be stably expressed irrespective of cisplatin treatment. Cytoskeletal rearrangements and high expression levels of individual heat shock proteins were detected in MSCs and may be partly responsible for the observed cisplatin resistance. The cisplatin-resistant phenotype of human MSCs supports the concept of further investigating these stem cells as a potential treatment option for cisplatin-induced tissue damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.